Georg Bernhard Landwehrmeyer, MD, FRCP

Principal Investigator Enroll-HD, Past Chairman of the Executive Committee of EHDN, Full Professor of Neurology, Director of the HD-Center Ulm. Department of Neurology, Ulm University, Ulm, Germany.

Dr. Landwehrmeyer has been Full Professor of Neurology ‘Clinical Neurobiology,’ University of Ulm, Ulm, Germany, since 2000. He is one of the founders of the European HD Network (EHDN), served for the first ten years since the constitution of EHDN as Chairman of the EHDN’s Executive Committee and continues to serve as leader of the EHDN project at Ulm University. Since 2011 Dr. Landwehrmeyer is the Principal Investigator of Enroll-HD, a worldwide, prospective, observational Huntington disease (HD) cohort study for HD families, sponsored by CHDI Foundation, USA. Dr. Landwehrmeyer directs the HD center at Ulm, a multi-disciplinary center providing genetic counselling, clinical in- and out-patient services as well as rehabilitation for HD affected families along with basic and translational science.

Dr. Landwehrmeyer received his medical degree from the Albert Ludwig University of Freiburg in Germany, where he also completed a residency in neurology, research training in neuropathology and molecular pharmacology, and a residency in neurology and psychiatry. Additional postgraduate training included studies at the Kantonsspital in Basel, Switzerland, and a research fellowship at the Massachusetts General Hospital, Harvard Medical School in Boston, Mass., USA.

He is also the recipient of research awards, for his work that focuses on neurodegenerative disorders, such as HD and Parkinson disease, ranging from bench work to clinical studies. He served as in several observational prospective cohort studies, including REGISTRY and Enroll-HD, contributed to Track-HD and to 26 phase I-III clinical trials, primarily in HD, often serving as principal investigator, including a first-in-man intrathecal application of antisense oligonucleotides to silence the huntingtin gene evaluating the safety, tolerability and efficacy of intrathecally administered agents as well as non-pharmacological interventions, evaluating the impact of physical activity and exercise in people with HD.

Dr. Landwehrmeyer’s extensive publications have appeared in numerous prestigious journals, including most recently, Cell, The New England Journal of Medicine, Lancet Neurology, Annals of Neurology, Brain, Neurology and JAMA Neurology. Other topics on which he has published include fronto-temporal degeneration, ALS, PSP and MSA. He presents his findings at numerous conferences worldwide.